Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations

NCT01501604 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01501604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01501604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2012
Completion date
August 31, 2013
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cholangiocarcinoma, colorectal cancer, lung cancer, solid tumors